The lower risk MDS patient at risk of rapid progression.

@article{Mittelman2010TheLR,
  title={The lower risk MDS patient at risk of rapid progression.},
  author={Moshe Mittelman and Howard S Oster and Michael Hoffman and Drorit Neumann},
  journal={Leukemia research},
  year={2010},
  volume={34 12},
  pages={1551-5}
}
Most patients with myelodysplastic syndrome (MDS) are classified at diagnosis as having a low/INT-I or INT-II/high risk disease, based on the classical International Prognostic Scoring System (IPSS) criteria. The low/INT-I risk patients are usually managed mildly with supportive care, including red blood cell (RBC) transfusions, erythroid stimulating agents (ESAs), other cytokines (G-CSF, platelet stimulating agents), as well as thalidomide and lenalidomide. Some patients receive… CONTINUE READING